Since the expression of CYP11A1 is rather low in prostate cancer cells and hardly detectable in clinical prostate cancer tissues, we next manly investigated the significance of ERRα-enhanced AKR1C3 expression or activity in the DHT biosynthesis in AR-positive prostate cancer cells. This evidence concerns the gene CYP11A1 and prostate carcinoma.